Regenxbio Shares Slide as FDA Pushes Back Key Drug Decision

Investors in biotechnology firm Regenxbio Inc. were met with a significant setback as the U.S. Food and Drug Administration (FDA) deferred its verdict on the company’s gene therapy candidate, RGX-121. The treatment, intended for Hunter Syndrome, will now face a regulatory decision in February 2026, a three-month extension from the original November 2025 deadline. This unexpected delay has sent the company’s stock tumbling and cast a shadow over its near-term prospects.

The postponement stems from Regenxbio’s submission of supplementary clinical data. The company provided additional information from all 13 participants in its pivotal study in response to an FDA request. Despite this extension, the regulatory process has seen some positive developments. The agency has reportedly completed its necessary inspections without issuing any citations and has not raised any new safety concerns related to the application. Regenxbio management has stated that its commercial preparation plans remain on track despite the revised timeline.

Market Reaction and Financial Strain

The financial markets responded negatively to the news, with Regenxbio’s stock price declining as much as 7% in a single trading session. This drop continues a troubling trend for the company, whose shares have lost over a third of their value in the past twelve months.

This regulatory hurdle arrives at a challenging financial juncture for the biotech firm. The company recently reported disappointing quarterly results in early August, posting a loss per share of -$1.38, which fell short of analyst expectations. Its net loss widened considerably, increasing by 33.7% year-over-year to $70.87 million.

Should investors sell immediately? Or is it worth buying Regenxbio?

A silver lining exists in the company’s liquidity position. With a cash reserve of $363.6 million, Regenxbio believes it has sufficient capital to fund its operations into early 2027. This financial cushion is critical for navigating the extended waiting period leading up to the potential approval of its flagship therapy.

Divergent Views from Major Investors and Analysts

The recent developments have elicited mixed reactions from institutional investors. Notable firms have taken opposing stances; BlackRock and Goldman Sachs significantly increased their holdings in Regenxbio during the second quarter. Conversely, Morgan Stanley and Citadel Advisors opted to reduce their exposure to the stock. Overall, institutional ownership remains dominant, accounting for nearly 90% of all shares.

Equity researchers have maintained a cautiously optimistic outlook despite the setbacks. Analysts at HC Wainwright and Chardan Capital recently reaffirmed their “Buy” recommendations on the stock. However, other firms, including Barclays and RBC Capital, have tempered their expectations by lowering their price targets. The consensus price target among analysts sits at approximately $28 per share, indicating a belief in substantial upside potential from current trading levels.

The central question for investors remains whether the additional review time will allow Regenxbio to satisfactorily address all FDA inquiries or if this delay signals more profound challenges ahead for its lead candidate.